Skip to main content
. Author manuscript; available in PMC: 2022 Jun 2.
Published in final edited form as: Clin Cancer Res. 2019 Mar 1;25(13):4168–4178. doi: 10.1158/1078-0432.CCR-18-2146

Figure 4: The influence of L-type calcium channel modulators on rituximab-induced apoptosis and tumor suppression.

Figure 4:

(A) The agonist of L-type calcium (Bay K8644) enhanced the rituximab-induced apoptosis, while the antagonist of L-type calcium channel (nimodipine) attenuated the rituximab-induced apoptosis (p<0.01) in DLBCL cell lines. (B) In PDX mouse models, rituximab combined with agonist (Bay K8644) markedly enhanced rituximab action (p<0.05). Neither its combination with antagonist (nimodipine) nor modulators of L-type calcium channel alone showed obvious effect on tumor growth (p>0.05).